The purpose of this study is to compare patients treated with pembrolizumab alone compared to those treated with chemotherapy plus pembrolizumab.
Learn more about the EA5221/ACHIEVE trial or call the Cancer Research Office at Phoenixville Hospital 610-983-1811 or Reading Hospital 484-628-8193.
